在胃癌中CLDN18.2:当前的治疗景观和未来的前景
Fei Zhang1, Ukyo Okazaki2, Izuma Nakayama3
1Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Journal of gastric cancer
|January 10, 2026
概括
克劳丁18.2是晚期胃癌的一个有希望的目标. 针对这种蛋白质的疗法,比如佐尔贝图西马布,正在将治疗转向以生物标志物为导向的方法,以获得更好的结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 克劳丁18.2 (CLDN18.2) 是一种在正常的胃上皮质中发现的紧结蛋白.
- 它在胃癌发生过程中经常被保留,使其成为癌症治疗的潜在目标.
研究的目的:
- 审查CLDN18.2在胃上皮和癌症中的生物学作用.
- 总结针对晚期胃癌 (AGC) 中的CLDN18.2的当前和未来治疗策略.
主要方法:
- 对临床试验 (SPOTLIGHT,GLOW) 的审查,评估抗CLDN18.2单克隆抗体索尔贝图西马布.
- 对CLDN18.2-向治疗的新兴管道的分析.
主要成果:
- 结合化疗的zolbetuximab确定了CLDN18.2作为AGC的可行的治疗标.
- 目前正在开发一系列针对CLDN18.2的药物,包括mAbs,双特异性抗体,ADC和CAR T细胞.
- 这些疗法为CLDN18.2-表达的AGC.提供了一个新的,有效的治疗途径.
结论:
- 针对性治疗的CLDN18.2代表了转向生物标志物驱动治疗的范式转变.
- 预计CLDN18.2向疗法将成为各种癌症阶段和类型的基石治疗.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.6K
03:05Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
Published on: February 16, 2024
1.5K
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K